GeneDx is trading 5.90% lower at $81.24 on August 31, 2026, with no clear company-specific catalyst identified.
- No announcement, earnings update, analyst action, or regulatory event surfaced for August 31; earlier August developments included reaffirmed guidance and a Seattle Children’s study.
- The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average are lower amid Middle East tensions, higher oil prices, and hawkish Federal Reserve concerns, leaving the decline unattributed.